Aspreva and Roche Announce Preliminary Results for Phase III Study
Evaluating CellCept in Lupus Nephritis
VICTORIA, BC, Canada and BASEL, Switzerland, June 27 /CNW/ -Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) andRoche today released preliminary results for a clinical trialcomparing CellCept (oral mycophenolate mofetil, MMF) to intravenouscyclophosphamide (IVC), which is the current standard of care, forinducing treatment response in the induction phase of patientssuffering fro...
Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin
in Complicated Urinary Tract Infections and Acute Pyelonephritis
ANAHEIM, Calif., May 19, 2007 /PRNewswire/ -- Data presentedtoday at a major medical meeting found that Levaquin (levofloxacin)750 mg tablets administered once-daily for five days is aseffective as standard therapy of ciprofloxacin (400/500 mg) for 10days for the treatment of complicated urinary tract infections(cUTI) and acute pyelo
nephritis (AP). Ortho-McNeil, Inc., the company t...